Hormonal Contraceptive Market Size Global Report, 2022 - 2030
Hormonal Contraceptive Market Share, Size, Trends, Industry Analysis Report, 2022 - 2030

Hormonal Contraceptive Market Share, Size, Trends, Industry Analysis Report, By Product; By Hormones (Combined Hormonal Contraceptive, Progestin-only Contraceptive); By Age; By End-Use; By Region; Segment Forecast, 2022 - 2030

  • Published Date:Sep-2022
  • Pages: 115
  • Format: PDF
  • Report ID: PM2570
  • Base Year: 2021
  • Historical Data: 2018-2020

Report Outlook

The global hormonal contraceptive market was valued at USD 16.38 billion in 2021 and is expected to grow at a CAGR of 4.3% during the forecast period. The market is expected to witness significant industry growth in the forecast period due to increased demand for family planning and the need to prevent unwanted pregnancies.

Hormonal Contraceptive Market
Know more about this report: Request for sample pages

Key factors facilitating the industry growth are growing awareness of hormonal preventives methods in emerging markets, increased investments in research and development of new preventives by significant players, and many government-supported initiatives to improve access to preventives.

The overall impact of the COVID-19 pandemic has significantly impacted the growth of the hormonal contraceptive market. It also disrupted the supply chain and manufacturing of preventives, affecting the availability of sources and supplies for proper family planning. However, the industry slowly stabilized and revived its family planning services, which normalized supply and manufacturing operations and increased the sales of preventives.

As the emergence of new technology and healthcare expenditure are prominent in Europe, significant growth is expected during the forecast period. In addition, the rise in new launches of products, the rapid growth of the economy and pharmaceutical industry, and a large number of targeted populations in the Asia Pacific are anticipated to grow over the forecast period.

Hormonal Contraceptive MarketKnow more about this report: Request for sample pages

Industry Dynamics

Growth Drivers
Growing awareness of the benefits and use of preventives is the leading factor that drives the global hormonal contraceptive market. Developing countries such as India, China, and Brazil, with ever-increasing populations, allow hormonal preventives to capture the industry, which will either eliminate or reduce unwanted pregnancies, the threat of sexual disorders, and abortion risks.

Furthermore, the more advancement in hormonal contraception that is convenient, effective, and has fewer side effects can also propel the industry's growth. In addition, factors that would drive the growth of hormonal contraceptive market awareness about modern preventives methods and the rise in manufacturing and availability of oral pills.

Report Segmentation

The market is primarily segmented based on product, Hormones, Age group, end-use, and region.

By Product

By Hormones

By Age group

By End-User

By Region

  • Oral contraceptive pills
  • Emergency contraceptive pills
  • Transdermal patches
  • Injectable birth control
  • Vaginal Rings
  • Combined
  • Progestin-only Contraceptive
  • 15-24 years
  • 25-34 years
  • 35-44 years
  • Above 44 years
  • Hospitals
  • Household
  • Clinics
  • Gynecology centers
  • Ambulatory Surgical Centers
  • North America (U.S., Canada)
  • Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
  • Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea)
  • Latin America (Brazil, Mexico, Argentina)
  • Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report: Request for sample pages

Contraceptive pills to accounted the largest share in 2021

Contraceptive pills among the product type have been attributed as the most significant revenue contributor in 2021. In addition, oral preventives pills are expected to continue their dominance during the forecast period due to easy availability, accessible combination oral pills, cost-effectiveness, and high success rate accounts to be the factor.

It is also expected that vaginal rings can showcase significant growth in the forecast period. This is because vaginal rings come up with new launches and are easy to use, with few side effects. Reports also have suggested vaginal ring also have their generic version.

Combined hormonal contraceptive are expected to spearhead the market growth

The demand for hormonal preventives is driven by the rising demand for innovative product launches. Growing awareness about reproductive and sexual health in the emerging market drives industry growth. In addition, with the increasing government initiatives and programs, more and more women are using preventives in developed and developing countries.

The hormonal contraceptive market is classified as a combined hormonal contraceptive and progestin-only contraceptives. The combined contraceptives segment currently leads the market and is expected to continue its dominance over the forecast period. The segment shows significant growth owing to the superior preventive efficacy and wide availability of combined hormonal preventives.

Age group ranging 15-24 years is expected to witness faster growth

The age group is segmented into 15-24 years, 25-34 years, 35-44 years, and above 44 years. Among all the age groups, the 15-24 years segment currently dominates the industry owing to the rising number of unplanned pregnancies.

This segment showcases prominent growth, owing to increased awareness about hormonal preventives, growing concerns about adolescent sexual behavior, and increased adoption of emergency preventives among adults. Premarital pregnancy usually leads to early school dropouts and abortion.

Household segment is expected to account for the largest share in 2030

The household segment is predicted to dominate the market over the forecast period owing to the increased consumption of oral pills at home to avoid unwanted pregnancy. The growing need for prevention at home has also enhanced health-related outcomes such as infant and maternal mortality, which is likely to impact revenue growth over the forecast period positively.

Ambulatory Surgical Centers and hospital is expected to be another significant segment to grow in the forecast period because of the availability of new intrauterine devices.

North America is expected to dominate over the forecast period

North America accounted for the highest share of the hormonal contraceptive market and is anticipated to dominate the marketplace within the forecast period. It is expected to continue with its position owing to its well-established infrastructure, huge pharmaceutical giants, and increased concern among teenagers about unwanted pregnancies.

The Asia Pacific is forecasted to be the second largest region for hormonal preventives because of the rising awareness about preventive and government initiatives to control the population. Improved pharmaceutical sectors in countries like India and Japan will positively impact revenue growth.

Competitive Insight

Some of the major players operating in the global market include Ansell ltd, Abbvie Inc, Afaxys inc, Agile Therapeutics, Bayer AG, Pfizer, inc, Church & Dwight,Co,Inc, Janssen Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Mylan N.V., Mayer Laboratories, Merck & co,Inc, Organon Group of companies, Pregna International Ltd, The Female Health Company.

Recent Developments

July 2022 Organon Group of companies and Cirqle Biomedical had a license agreement for novel investigational non-hormonal, on-demand preventives people. The company believes in innovation and can bring on new options for women.

August 2022 Bayer’s Long-acting reversible intrauterine system named Mirena is now approved by the U.S. FDA, which offers the most extended preventives duration and has an efficacy of up to six to eight years.

February 2020, Afaxys Pharma LLC and TherapeuticsMD Inc. announced about their agreement to expand access to ANNOVERA which has ethinyl Estradiol.

Polyurea Coatings Market Report Scope

Report Attributes


Market size value in 2021

USD 16.38 billion

Revenue forecast in 2030

USD 23.81 billion


4.3% from 2022 - 2030

Base year


Historical data

2018 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD billion and CAGR from 2022 to 2030

Segments covered

 By Product/Method (Pills, Implants & Patches); By Hormones (Combined and progestin); By Age; By End-User; By Region;

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa

Key companies

Ansell ltd, Abbvie Inc, Afaxys inc, Agile Therapeutics, Bayer AG, Pfizer, inc, Church & Dwight,Co,Inc, Janssen Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Mylan N.V., Mayer Laboratories, Merck & co,Inc, Organon Group of companies, Pregna International Ltd, The Female Health Company